Drug intelligence / Profile preview

ticarcillin

Development stage
Unknown
Lead developer
GSK
Modality
Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Ticarcillin is a semisynthetic, extended-spectrum carboxypenicillin antibiotic belonging to the beta-lactam class. It is primarily used for the treatment of moderate-to-severe infections caused by susceptible Gram-negative bacteria, especially Pseudomonas aeruginosa and Proteus vulgaris. Its mechanism of action involves inhibition of bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby preventing cross-linking of peptidoglycan chains during cell division, which leads to bacterial cell lysis and death. Like other penicillins, it contains a β-lactam ring that can be hydrolyzed by β-lactamases produced by resistant bacteria[1][2][3][5]. Ticarcillin is not absorbed orally and must be administered intravenously or intramuscularly[3]. It has also been used in molecular biology as an alternative to ampicillin for selection purposes due to its stability in culture media[3].

Brand names
Ticar
Other names
TicarcilinaTicarcillineTicarcillinumα-carboxy-3-thienylmethylpenicillin
02

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on ticarcillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ticarcillin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call